Pacira BioSciences (PCRX) Other Non-Current Liabilities (2010 - 2026)

Pacira BioSciences' Other Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $15.8 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities fell 10.12% year-over-year to $15.8 million; the TTM figure through Mar 2026 stood at $15.8 million (down 10.12% YoY), while the FY2025 annual figure was $20.6 million, up 22.33% from the prior year.
• Other Non-Current Liabilities was $15.8 million for Q1 2026 at Pacira BioSciences, down from $20.6 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $56.5 million in Q1 2022 to a low of $11.6 million in Q1 2023.
• Historically, Other Non-Current Liabilities has averaged $21.2 million across 5 years, with a median of $17.8 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities jumped 357.52% in 2022, then slumped 79.52% in 2023.
• A 5-year view of Other Non-Current Liabilities shows it stood at $28.1 million in 2022, then slumped by 51.74% to $13.6 million in 2023, then rose by 23.9% to $16.8 million in 2024, then rose by 22.33% to $20.6 million in 2025, then dropped by 23.25% to $15.8 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $15.8 million (Q1 2026), $20.6 million (Q4 2025), and $17.8 million (Q3 2025), per Business Quant data.